AIDS:中缅边境地区注射吸毒人群HIV-1分子流行病学研究获进展

2012-05-25 中科院昆明动物所 中科院昆明动物所

吸毒人群是我国HIV-1感染的高危人群,注射吸毒(Injecting Drug Users, IDUs) 尤其是跨境注射吸毒导致的艾滋病重组流行已成为我国艾滋病传播的重要途径之一。由于毗邻著名的毒品生产基地“金三角”,云南省特别是边境地区的吸毒现象较为普遍。1989年年底,我国在云南省瑞丽市吸毒者中首次发现规模人群感染艾滋病。在过去的回顾性研究中,发现印度HIV-1 B’亚型和泰国C亚型,沿着毒品

吸毒人群是我国HIV-1感染的高危人群,注射吸毒(Injecting Drug Users, IDUs) 尤其是跨境注射吸毒导致的艾滋病重组流行已成为我国艾滋病传播的重要途径之一。由于毗邻著名的毒品生产基地“金三角”,云南省特别是边境地区的吸毒现象较为普遍。1989年年底,我国在云南省瑞丽市吸毒者中首次发现规模人群感染艾滋病。在过去的回顾性研究中,发现印度HIV-1 B’亚型和泰国C亚型,沿着毒品运输途径,经缅甸传入云南,在云南边境的注射吸毒人群中重组形成HIV-1流行重组型(Circulating recombinant forms, CRF):CRF07_BC和CRF08_BC,然后经不同的毒品转运途径在中国大流行。因此,了解当前中缅边境地区注射吸毒人群HIV-1流行重组情况,将为动态监测我国注射吸毒HIV-1感染人群中病毒亚型及其变化,预测AIDS流行分布趋势提供科学依据。

为了解该人群的HIV病毒流行特征,中国科学院昆明动物研究所动物模型与人类疾病机理重点实验室博士后庞伟等人在导师郑永唐研究员的指导下,与江苏大学生命科学院张驰宇副教授合作,从中缅边境缅北地区注射吸毒人群HIV-1感染者的血浆样品中,扩增了HIV-1的4个基因片段,进行了HIV-1分型和重组分析。结果发现,在该人群中, HIV-1表现出极高的亚型间重组率和极罕见的重组特征:共鉴定出68个重组型,这些重组主要发生在CRF01_AE、B和C亚型之间。B/C 亚型和CRF01_AE/B/C 重组型是最主要的重组型别,分别占重组型的54.4% 和42.6%。在这68个重组型中,其中的64个重组模式未见报道,为HIV-1独特重组型(unique recombination forms, URF)。其中,在这4个基因片段中,pol和vif-env基因重组最为频繁。pol基因的亚型间重组率为78.3%; vif-env基因的亚型间重组率为77.6%。这2个基因的重组率远高于周边地区的云南省东南地区、云南省德宏州和缅甸中部地区。该研究结果表明中缅边境缅北地区是HIV-1重组的“大熔炉”。在该地区注射吸毒人群中产生的大量新的重组HIV-1病毒提示我国应加强中缅边境地区HIV-1病毒的亚型监测和防控工作。

该研究成果近期已发表在国际艾滋病研究领域著名学术期刊《艾滋病》AIDS上。该研究得到了国家重大科技专项、国家自然科学基金、艾滋病亚洲区域项目等项目的资助及云南省疾病预防控制中心的协助。

Extensive and complex HIV-1 recombination between B', C and CRF01_AE among IDUs in south-east Asia.

Pang W, Zhang C, Duo L, Zhou YH, Yao ZH, Liu FL, Li H, Tu YQ, Zheng YT.

OBJECTIVE: : To investigate the subtype characterization of HIV-1 among IDUs in northern Myanmar. DESIGN: : A molecular epidemiological investigation was conducted among IDUs in Laza and Maizayang cities of northern Myanmar. METHODS: : A total of 83 HIV-1-positive serums were collected from consenting IDUs during June to August 2009. HIV-1 p17, pol, vif-env, C2V3 fragments were amplified and sequenced. Phylogenetic and bootscanning analyses were performed. RESULTS: : A very high proportion (86.1%) of HIV-1 intersubtype recombinants and very low proportion of subtypes B' (3.8%), C (7.6%) and CRF01_AE (1.3%) were found in this HIV-infected IDUs cohort. These recombinants cover all four kinds of recombination forms formed among CRF01_AE, B and C. The B/C and CRF01_AE/B/C recombinants are the two most dominant recombinants, accounting for 54.4 and 42.6% of all cases, respectively, and indicating the ongoing generation of extensive and complex HIV-1 recombination among CRF01_AE, B' and C in northern Myanmar. Intriguingly, most recombinants have different chimeric patterns from each other, forming 64 unique recombination forms (URFs) that are quite distinct from any previously identified circulating recombinant forms (CRFs) and URFs in Asia. CONCLUSION: : The extremely high proportion of intersubtype recombinants, especially CRF01_AE/B'/C recombinants (42.6%), strongly suggests that northern Myanmar is a big forge for HIV-1 recombination among CRF01_AE, B' and C.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033793, encodeId=53cc2033e9386, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Jul 15 01:57:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719719, encodeId=812e1e197194c, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Fri Oct 05 16:57:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801168, encodeId=6cfc180116831, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Dec 13 11:57:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365590, encodeId=6f44136559034, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411190, encodeId=2b5e14111908d, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458379, encodeId=a12e14583e9c3, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
    2012-07-15 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033793, encodeId=53cc2033e9386, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Jul 15 01:57:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719719, encodeId=812e1e197194c, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Fri Oct 05 16:57:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801168, encodeId=6cfc180116831, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Dec 13 11:57:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365590, encodeId=6f44136559034, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411190, encodeId=2b5e14111908d, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458379, encodeId=a12e14583e9c3, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
    2012-10-05 millore
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033793, encodeId=53cc2033e9386, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Jul 15 01:57:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719719, encodeId=812e1e197194c, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Fri Oct 05 16:57:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801168, encodeId=6cfc180116831, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Dec 13 11:57:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365590, encodeId=6f44136559034, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411190, encodeId=2b5e14111908d, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458379, encodeId=a12e14583e9c3, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033793, encodeId=53cc2033e9386, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Jul 15 01:57:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719719, encodeId=812e1e197194c, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Fri Oct 05 16:57:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801168, encodeId=6cfc180116831, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Dec 13 11:57:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365590, encodeId=6f44136559034, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411190, encodeId=2b5e14111908d, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458379, encodeId=a12e14583e9c3, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
    2012-05-27 cooco
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033793, encodeId=53cc2033e9386, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Jul 15 01:57:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719719, encodeId=812e1e197194c, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Fri Oct 05 16:57:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801168, encodeId=6cfc180116831, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Dec 13 11:57:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365590, encodeId=6f44136559034, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411190, encodeId=2b5e14111908d, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458379, encodeId=a12e14583e9c3, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]
    2012-05-27 xugumin
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033793, encodeId=53cc2033e9386, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Sun Jul 15 01:57:00 CST 2012, time=2012-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719719, encodeId=812e1e197194c, content=<a href='/topic/show?id=0a3a3941340' target=_blank style='color:#2F92EE;'>#吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39413, encryptionId=0a3a3941340, topicName=吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=112932803031, createdName=millore, createdTime=Fri Oct 05 16:57:00 CST 2012, time=2012-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801168, encodeId=6cfc180116831, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Dec 13 11:57:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365590, encodeId=6f44136559034, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411190, encodeId=2b5e14111908d, content=<a href='/topic/show?id=91e96538eee' target=_blank style='color:#2F92EE;'>#流行病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65387, encryptionId=91e96538eee, topicName=流行病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=xugumin, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458379, encodeId=a12e14583e9c3, content=<a href='/topic/show?id=abec649e801' target=_blank style='color:#2F92EE;'>#注射吸毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64978, encryptionId=abec649e801, topicName=注射吸毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4066051585, createdName=cqlidoudou, createdTime=Sun May 27 10:57:00 CST 2012, time=2012-05-27, status=1, ipAttribution=)]

相关资讯

JBC:结核病人更容易感染HIV-1

众所周知,感染结核杆菌的病人更可能会感染HIV-1,但是结核杆菌刺激HIV-1长末端重复序列(LTR)的转录机制尚不明确。近日,印度DNA指纹诊断中心的Sangita Mukhopadhyay等人研究发现,结核杆菌PPE蛋白Rv1168c能够增强HIV-1 LTR启动子的转录,该研究促进了HIV-1及结核杆菌共同感染病人中HIV-1发病学的研究,相关论文发表在3月15日美国《生化周刊》(JBC)上